DME cases to rise by 20% in seven major markets by 2034: GlobalData

Cases are projected to reach more than 3.4 million by 2034.

Diagnosed prevalent cases of diabetic macular edema (DME) across the seven major markets (7MM) are expected to increase to 3.46 million in 2034 from 2.89 million in 2024, according to a forecast by GlobalData.

GlobalData predicts an annual growth rate (AGR) of 1.99% in DME cases amongst the 7MM, which includes the US, France, Germany, Italy, Spain, the UK, and Japan.

GlobalData estimates that in 2024, approximately 81% of diagnosed prevalent cases of DME in diabetes were center involving or ci-DME, whereas only 19% of diagnosed prevalent cases of DME in diabetes were non-center involving or nci-DME.

The report also showed who was getting affected more by the disease with men accounting for 57% cases compared to 43% in women whilst adults 50 years old and above accounted for 84% compared to 20-49 year olds who were affected in 16% of cases.

GlobalData estimates that in 2024, approximately 81% of diagnosed prevalent cases of DME in diabetes were center involving or ci-DME, whereas only 19% of diagnosed prevalent cases of DME in diabetes were non-center involving or nci-DME.

“Globally, DME represents the major cause of vision impairment in diabetic patients with an increasing prevalence.”, said Antara Bhattacharya, Associate Project Manager, Epidemiology at GlobalData.

“Research based approach by working with a medical team on treatment and disease management and adopting lifestyle changes and coping strategies for reduced vision can extend our understanding of the disease.” Bhattacharya added.